bremelanotide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Mechanical tenderization, such as pounding or piercing. The tenderization that occurs through cooking, such as braising. Tenderizers in the form of naturally occurring enzymes known as proteases, which can be added to food before cooking. Examples of enzymes used for tenderizing: papain from papaya, trypsin and chymotrypsin from honey, bromelain from pineapple and actinidain from kiwifruit. Marinating the meat with vinegar, wine, lemon juice, buttermilk or yogurt. Brining the meat in a salt solution (brine). Dry aging of meat at 0 to 2 °C (32 to 36 °F). Velveting Sodium bicarbonate
=== Post-synthetic modification === Although the three-dimensional structure and internal environment of the pores can be in theory controlled through proper selection of nodes and organic linking groups, the direct synthesis of such materials with the desired functionalities can be difficult due to the high sensitivity of MOF systems. Thermal and chemical sensitivity, as well as high reactivity of reaction materials, can make forming desired products challenging to achieve. The exchange of guest molecules and counter-ions and the removal of solvents allow for some additional functionality but are still limited to the integral parts of the framework. The post-synthetic exchange of organic linkers and metal ions is an expanding area of the field and opens up possibilities for more complex structures, increased functionality, and greater system control.
{\displaystyle {\begin{aligned}\alpha _{{\ce {H2A}}}&={\frac {{\ce {[H+]^2}}}{{\ce {[H+]^2}}+[{\ce {H+}}]K_{1}+K_{1}K_{2}}}={\frac {{\ce {[H2A]}}}{{\ce {{[H2A]}}}+[HA^{-}]+[A^{2-}]}}\\\alpha _{{\ce {HA^-}}}&={\frac {[{\ce {H+}}]K_{1}}{{\ce {[H+]^2}}+[{\ce {H+}}]K_{1}+K_{1}K_{2}}}={\frac {{\ce {[HA^-]}}}{{\ce {[H2A]}}+{[HA^{-}]}+{[A^{2-}]}}}\\\alpha _{{\ce {A^{2-}}}}&={\frac {K_{1}K_{2}}{{\ce {[H+]^2}}+[{\ce {H+}}]K_{1}+K_{1}K_{2}}}={\frac {{\ce {[A^{2-}]}}}{{\ce {{[H2A]}}}+{[HA^{-}]}+{[A^{2-}]}}}\end{aligned}}}
Sources: en.wikipedia.org
Cultivation methods resulting in larger yields are categorized as "bulk growing". Bulk growing allows cultivators to operate on a larger scale, but require a greater investment of time, money, and knowledge. While small-scale grows utilize spore syringes to inject spore solution into cakes, bulk methods instead use grain spawn as primary nutrition for the subsequent growth. Additionally, cultivators must develop solid sterile technique in working with agar. Instead of inoculating grain with spores, growers instead germinate spores on agar plates, then transfer the resultant healthy mycelium to the grain jars. Once the grain is colonized with clean mycelial growth, users inoculate their bulk substrates with the grain in a process known as "spawning." Bulk substrates are frequently a mix of coir, vermiculite and gypsum due to not requiring pasteurization or sterilization. However, some utilize blends of manure-based substrates or straw; substrates which always require pasteurization with open-air spawning. After spawning, the healthy mycelium will colonize the bulk substrate, and given proper conditions, eventually fruit mushrooms. Terence and Dennis McKenna made P. cubensis particularly famous when they published Psilocybin: Magic Mushroom Grower's Guide in the 1970s upon their return from the Amazon rainforest, having deduced new methods (based on pre-existing techniques originally described by J.P. San Antonio) for growing psilocybin mushrooms and assuring their audience that P. cubensis were amongst the easiest psilocybin-containing mushrooms to cultivate.
It is also formed by the degradation of precursors such as some fluorotelomers. PFOA is used as a surfactant because it can lower the surface tension of water more than hydrocarbon surfactants while having exceptional stability due to having perfluoroalkyl tail group. The stability of PFOA is desired industrially but is a cause of concern environmentally. The primary manufacturer of perfluorooctanesulfonic acid (PFOS), 3M, began a production phase-out in 2002 in response to concerns expressed by the U.S. Environmental Protection Agency (EPA). Eight other companies agreed to gradually phase out the manufacturing of the chemical by 2015. By 2014, EPA had listed PFOA and perfluorooctanesulfonates (salts of perfluorooctanesulfonic acid, PFOS) as emergent contaminants:
=== Overview === The sequence motif discovery process has been well-developed since the 1990s. In particular, most of the existing motif discovery research focuses on DNA motifs. With the advances in high-throughput sequencing, such motif discovery problems are challenged by both the sequence pattern degeneracy issues and the data-intensive computational scalability issues. Process of discovery
Sources: en.wikipedia.org
== Diagnosis == A fasting blood sugar level of ≥ 7.0 mmol / L (126 mg/dL) is used in the general diagnosis of diabetes. There are no clear guidelines for the diagnosis of LADA, but the criteria often used are that the patient develops the disease in adulthood, does not need insulin treatment for the first 6 months after diagnosis, and has autoantibodies in the blood. It is recommended that glutamic acid decarboxylase autoantibody (GADA), islet cell autoantibody (ICA), insulinoma-associated (IA-2) autoantibody, and zinc transporter autoantibody (ZnT8) testing be performed to correctly diagnose diabetes. Persons with LADA typically have low, although sometimes moderate, levels of C-peptide as the disease progresses. Those with insulin resistance or type 2 diabetes are more likely to have high levels of C-peptide.
Cellular adhesion and development. The adhesion between cells is a characteristic of multicellular organisms that enables tissue specialization and therefore increases cell complexity. Adhesion of cell epithelia involves the actin cytoskeleton in each of the joined cells as well as cadherins acting as extracellular elements with the connection between the two mediated by catenins. Interfering in actin dynamics has repercussions for an organism's development, in fact actin is such a crucial element that systems of redundant genes are available. For example, if the α-actinin or gelation factor gene has been removed in Dictyostelium individuals do not show an anomalous phenotype possibly due to the fact that each of the proteins can perform the function of the other. However, the development of double mutations that lack both gene types is affected. Gene expression modulation. Actin's state of polymerization affects the pattern of gene expression. In 1997, it was discovered that cytocalasin D-mediated depolymerization in Schwann cells causes a specific pattern of expression for the genes involved in the myelinization of this type of nerve cell. F-actin has been shown to modify the transcriptome in some of the life stages of unicellular organisms, such as the fungus Candida albicans. In addition, proteins that are similar to actin play a regulatory role during spermatogenesis in mice and, in yeasts, actin-like proteins are thought to play a role in the regulation of gene expression.
== Diagnosis == Typically, seborrhoeic dermatitis is a clinical diagnosis based on a physician's expertise in identifying and differentiating skin conditions based on the history of the individual and the appearance of the skin. Seborrhoeic dermatitis may also be diagnosed with additional testing. The least invasive test is a visual inspection in the clinic using a Wood's lamp. A KOH test can also be used, where skin scraping of the affected skin may also be taken and prepared with potassium hydroxide (KOH) and visualized under a microscope to look for Malassezia or other microbiological cells. Additionally, a fungal culture of the affected skin may be taken to attempt to grow and identify the causative organism.
=== 1968 === January 30: Tet Offensive in South Vietnam begins. March 1: The years of Lead start in Italy with the Battle of Valle Giulia clash between far-right and far-left militants. March 12: Mauritius becomes independent from the UK under Commonwealth status. March 18: The Moro conflict begins in Southern Philippines. March 30: Johnson suspends bombings over North Vietnam and announces he is not running for reelection. June 8: Tet Offensive ends; while an American military victory, it raises questions over America's military chances in Vietnam. June 17: The Second Malayan Emergency begins. July 1: The Treaty on the Non-Proliferation of Nuclear Weapons (NPT) is opened for signature. July 17: Abdul Rahman Arif, the President of Iraq at that time was overthrown by a coup staged by Iraq Ba'athist Party. The revolution eventually lead to the installation of the Ba'athist government in Iraq. August 20: Prague Spring Reforms in Communist Czechoslovakia result in Warsaw Pact, led by Soviet Red Army, crushing Czechoslovak revolt. September 6: Swaziland becomes independent from the UK. October 3: Peruvian General Juan Velasco Alvarado overthrows President Fernando Belaunde Terry in a military coup. October 12: Spanish Guinea (modern day Equatorial Guinea) becomes independent from Spain. December 23: The captain and crew of the USS Pueblo are released by North Korea. December 21–27: The launch of Apollo 8, the first crewed spaceflight to enter the gravitational influence of another celestial body and to orbit the Moon.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.